{"id":730018,"date":"2023-02-09T06:11:59","date_gmt":"2023-02-09T11:11:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-09T06:11:59","modified_gmt":"2023-02-09T11:11:59","slug":"shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/","title":{"rendered":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">AUSTIN, TX &amp; DURHAM, NC, Feb.  09, 2023  (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023.<\/p>\n<p>\n        <strong>About Shattuck Labs, Inc.<\/strong><br \/>\n        <br \/>Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC\u00ae, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company\u2019s lead SL-172154 (SIRP\u03b1-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN\u2122, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.<\/p>\n<p>The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact: <\/strong><br \/>\n        <br \/>Conor Richardson<br \/>Vice President of Investor Relations<br \/>Shattuck Labs, Inc.<br \/>InvestorRelations@shattucklabs.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjEwMzJhNzQtNDY2Zi00MDcyLTg2ZWItZmYyYjFjY2NlMTJlLTEyMTQzODQ=\/tiny\/Shattuck-Labs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, TX &amp; DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023. About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC\u00ae, platform simultaneously inhibit checkpoint molecules and activate costimulatory &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-730018","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, TX &amp; DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023. About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC\u00ae, platform simultaneously inhibit checkpoint molecules and activate costimulatory &hellip; Continue reading &quot;Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T11:11:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-09T11:11:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\",\"datePublished\":\"2023-02-09T11:11:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk","og_description":"AUSTIN, TX &amp; DURHAM, NC, Feb. 09, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference being held virtually February 13-16, 2023. About Shattuck Labs, Inc. Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC\u00ae, platform simultaneously inhibit checkpoint molecules and activate costimulatory &hellip; Continue reading \"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-09T11:11:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference","datePublished":"2023-02-09T11:11:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/","name":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=","datePublished":"2023-02-09T11:11:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NTg2MCM1NDAwMjU0IzIyMDI4MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-announces-participation-in-upcoming-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=730018"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/730018\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=730018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=730018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=730018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}